Literature DB >> 30296309

5 Points on Meniscal Allograft Transplantation.

Matthew E Gitelis, Rachel M Frank, Maximillian A Meyer, Gregory Cvetanovich, Brian J Cole1.   

Abstract

Meniscus allograft transplantation (MAT) has yielded excellent long-term functional outcomes when performed in properly indicated patients. When evaluating a patient for potential MAT, it is imperative to evaluate past medical history and past surgical procedures. The ideal MAT candidate is a chronologically and physiologically young patient (<50 years) with symptomatic meniscal deficiency. Existing pathology in the knee needs to be carefully considered and issues such as malalignment, cartilage defects, and/or ligamentous instability may require a staged or concomitant procedure. Once an ideal candidate is identified, graft selection and preparation are critical steps to ensure a proper fit and long-term viability of the meniscus. When selecting the graft, accurate measurements must be taken, and this is most commonly performed using plain radiographs for this. Graft fixation can be accomplished by placing vertical mattress sutures and tying those down with the knee in full extension.

Entities:  

Mesh:

Year:  2018        PMID: 30296309     DOI: 10.12788/ajo.2018.0069

Source DB:  PubMed          Journal:  Am J Orthop (Belle Mead NJ)        ISSN: 1078-4519


  2 in total

1.  Return to Work Following Arthroscopic Meniscal Allograft Transplantation.

Authors:  Avinesh Agarwalla; Joseph N Liu; David R Christian; Grant H Garcia; Gregory L Cvetanovich; Anirudh K Gowd; Adam B Yanke; Brian J Cole
Journal:  Cartilage       Date:  2020-07-02       Impact factor: 3.117

2.  Treatment of post-meniscectomy knee symptoms with medial meniscus replacement results in greater pain reduction and functional improvement than non-surgical care.

Authors:  Kenneth R Zaslav; Jack Farr; Richard Alfred; R Maxwell Alley; Michael Dyle; Andreas H Gomoll; Christian Lattermann; Brian P McKeon; Christopher C Kaeding; Thomas Giel; Elliott B Hershman
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2021-04-21       Impact factor: 4.342

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.